Tabea Moll

TL;DR: A resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion is identified, and this study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.

TL;DR: IMPRES is a predictor of ICB response in melanoma which encompasses 15 pairwise transcriptomics relations between immune checkpoint genes and achieves an overall accuracy of AUC = 0.83, outperforming existing predictors and capturing almost all true responders while misclassifying less than half of the nonresponders.

TL;DR: In this paper, the authors found a myeloid cell-attracting hub at the tumor-luminal interface associated with tissue damage and an MMRd-enriched immune hub within the tumor.

TL;DR: In this article, a high-resolution map of the evolutionary dynamics of resistance to ICB, characterizes a de-differentiated neural-crest tumor population in melanoma immunotherapy resistance and describes site-specific differences in tumor-immune interactions via longitudinal analysis of a patient with melanoma with an unusual clinical course.

TL;DR: Investigation of the role of ECM remodeling by the collagenase, MT1-MMP, in conferring resistance of v-Raf murine sarcoma viral oncogene homolog B1-mutant melanoma to BRAF inhibitor (BRAFi) therapy found it pivotal to an ECM-based signaling pathway that confers resistance to BRAFi therapy.